Cytori Therapeutics Inc (NASDAQ:CYTX) hit a new 52-week low on Wednesday . The stock traded as low as $0.27 and last traded at $0.28, with a volume of 1465300 shares changing hands. The stock had previously closed at $0.30.

Several equities research analysts recently weighed in on the stock. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 19th. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.

Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. During the same quarter in the previous year, the firm posted ($0.26) EPS. research analysts expect that Cytori Therapeutics Inc will post -0.62 earnings per share for the current year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. boosted its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 612,304 shares of the biotechnology company’s stock after purchasing an additional 275,653 shares during the period. Vanguard Group Inc. owned approximately 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent quarter. 7.41% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Stock Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related stocks with our FREE daily email newsletter.